# OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

> **NCT07406217** · PHASE2 · RECRUITING · sponsor: **Calmy Alexandra** · enrollment: 256 (estimated)

## Conditions studied

- COVID-19
- Immunodeficiency

## Interventions

- **DRUG:** Paxlovid 5 days
- **DRUG:** Paxlovid 10 days

## Key facts

- **NCT ID:** NCT07406217
- **Lead sponsor:** Calmy Alexandra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-27
- **Primary completion:** 2026-04-10
- **Final completion:** 2026-06-30
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406217, "OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07406217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*